

Subject, city, state	Effective date
LAUGHLIN, HAROLD JASON JR, EDMOND, OK .....	04/19/2001
LIPPIELLO, JENNIE A, NEWFOUNDLAND, NJ .....	04/19/2001
LONG, TIMOTHY J, PHILADELPHIA, PA .....	04/19/2001
MITCHELL, AIDAN JAMES, NEW YORK, NY .....	04/19/2001
NEWMAN, MICHAEL J, S AMBOY, NJ .....	04/19/2001
NGUYEN, TRINH MY, PORTLAND, OR .....	04/19/2001
ROTHMAN, JERRY K, DULUTH, MN .....	03/14/2001
SCAFIDI, SCOTT J, N MYRTLE BEACH, SC .....	04/19/2001
SMITH, GEORGE EDMOND, PHILADELPHIA, PA .....	04/19/2001
TAYLOR, LISA M, NEW LONDON, CT .....	04/19/2001
Owners of Excluded Entities:	
KLINE, MATTHEW M, MECHANICSBURG, PA .....	05/24/1999
O'SHAUGHNESSY, TIMOTHY J, BETHESDA, MD .....	05/24/1999

Dated: April 3, 2001.

**Maureen Byer,**

*Acting Director, Health Care Administrative  
Sanctions, Office of Inspector General.*

[FR Doc. 01-9091 Filed 4-11-01; 8:45 am]

**BILLING CODE 4150-04-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health,  
Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### Vector Systems for the Generation of Adeno-Associated Virus Particles

JA Chiorini, R Kotin, B Safer, E Urcelay  
(NHLBI)

Serial No. 08/157,740 filed 24 Nov 1993,  
now US Patent 5,693,531 issued 02  
Dec 1997

Licensing Contact: Susan S. Rucker;  
301/496-7056 ext. 245; e-mail:  
*ruckers@od.nih.gov*

This patent relates to a system for the production of recombinant AAV vectors for gene therapy. More particularly, the patent relates to an AAV vector system which utilizes an inducible system for the production of high titer virus. The first vector contains a 5' and 3' AAV ITR flanking the heterologous gene of interest to be delivered. The second vector contains an inducible origin of replication and the AAV rep and cap proteins. This second vector provides a means for increasing the amount of AAV structural proteins available for the production of infectious AAV particles. In the presence of the inducing agent these two vector are able to produce high titer of infectious AAV particles which can be used to deliver the heterologous gene of interest.

This work has been published, in part, at Chiorini, JA, et al. "High-efficiency transfer of the T cell co-stimulatory molecule B72 to lymphoid cells using high-titer recombinant adeno-associated virus vectors" *Hum Gene Ther* 6(12):1531-41 (Dec 1995).

#### Immunization from an Immunized Allogeneic Bone Marrow Donor

Larry W. Kwak, Dan L. Longo (NCI)  
Serial No. 08/153,464 filed 17 Nov 1993;  
U.S. Patent 5,861,158 issued 19 Jan  
1999

Licensing Contact: Elaine White; 301/  
496-7056 ext. 282; e-mail:  
*gesee@od.nih.gov*

A novel method has been developed for transferring immunity against specific types of tumors from a bone marrow donor to a recipient. Although there have been major advances in studying the biology of B-cell and leukemia cancers in recent years, progress in the treatment of such diseases has been modest since the treatment of alkylating agents more than 30 years ago. An approach using intensive, high-dose chemoradiotherapy combined with bone marrow

transplantation (to help improve tolerance of bone marrow cells to intense therapy) is presently being explored by several groups of investigators. However, although this type of therapy has improved initial responsive rates, the vast majority of patients (90 percent) eventually relapse.

The current invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. This method offers a novel means for conferring immunity against, and thereby treating, B-cell and leukemia cancers as well as other types of cancers.

#### A Murine Melanoma Transduced with CCR7 as a Model of Enhanced Metastasis to Lymph Nodes

Sam T. Hwang (NCI)  
DHHS Reference No. E-104-01/0  
Licensing Contact: Elaine White; 301/  
496-7056 ext. 282; e-mail:  
*gesee@od.nih.gov*

The current invention embodies a B16 murine melanoma cell line which has been stably transduced with the gene for CCR7, a gene which promotes the migration of activated dendritic cells into lymphatic vessels. This transduced cell line has been shown to metastasize much more efficiently to lymph nodes than non-transduced cells. While the spontaneous rate of metastasis to lymph nodes is quite low for non-transduced B16 cells, the inventor has found 200-1400 times more melanoma-specific mRNA in the lymph nodes of mice which have been injected with the CCR7-expressing melanoma cells. As melanoma in humans first metastasizes by invading the lymphatics and migrating to the draining lymph nodes, the transduced B16 cell line embodied in this invention appears to represent a

valuable model system for identification and testing of agents to be used in prevention or reduction of melanoma metastasis via a lymphatic route. The cell line is available for licensing via Biological Materials License Agreements.

Dated: April 3, 2001.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 01-9013 Filed 4-11-01; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Prospective Grant of Co-Exclusive License: Compositions and Methods Related to the Detection of Philadelphia Chromosome Translocations**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use worldwide co-exclusive license to DAKO Corporation, in all countries except Japan, to practice the invention embodied in U.S. Patent 4,681,840 entitled U.S. "Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA", which issued on July 21, 1987 from Patent Application Serial No. 06/571,911 filed on January 18, 1984. DAKO Corporation is a corporation of Denmark having a place of business in Carpinteria, California. The patent rights in this invention have been assigned to the United States of America, as represented by the Department of Health and Human Services.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 11, 2001 will be considered.

**ADDRESSES:** Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Catherine Joyce, Ph.D., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 258; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** The patent applications describe compositions and methods related to the detection of chromosomal translocations, particularly the bcr/abl translocation which has been demonstrated to be associated with the Philadelphia chromosome and chronic myelogenous leukemia.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH has received written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of the invention for research and clinical nucleic acid hybridization techniques for the detection of bcr/abl translocations.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 3, 2001.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 01-9014 Filed 4-11-01; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **National Center for Research Resources; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Research Resources Special Emphasis Panel, Clinical Research.

*Date:* May 30, 2001.

*Time:* 7:00 am to Adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101.

*Contact Person:* John L. Meyer, PhD, Deputy Director, Office of Review, National Center for Research Resources, National Institutes of Health, 6705 Rockledge Drive, MSC 7965, One Rockledge Centre, Room 6018, Bethesda, MD 20892-7965, 301-435-0806, meyerj@ncrr.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333; 93.371, Biomedical Technology; 93.389, Research Infrastructure, National Institutes of Health, HHS)

Dated: April 3, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-9009 Filed 4-11-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **National Center for Research Resources; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.